US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
NGM Biopharmaceuticals Inc (NGM)
NGM Biopharmaceuticals Inc (NGM) ニュース

NGM

NGM Biopharmaceuticals (NGM)

NGM Biopharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NGM

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/05	22 : 19	GlobeNewswire Inc.	NGM Bio Announces Closing of Tender Offer	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/03/20	06 : 30	GlobeNewswire Inc.	NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/03/12	05 : 15	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/03/12	05 : 13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/03/12	05 : 05	GlobeNewswire Inc.	NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/03/09	07 : 32	Edgar (US Regulatory)	Form SC 13E3 - Going private transaction by certain issuers	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/03/09	07 : 21	Edgar (US Regulatory)	Form SC 14D9 - Solicitation, recommendation statements	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/02/27	07 : 11	Edgar (US Regulatory)	Form SC14D9C - Written communication relating to third party tender offer	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/02/27	07 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/02/26	23 : 03	GlobeNewswire Inc.	NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/02/21	06 : 01	GlobeNewswire Inc.	NGM Bio to Participate in the Cowen 44th Annual Health Care Conference	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/02/15	08 : 12	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/01/22	20 : 09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/01/19	08 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/01/19	08 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/01/19	08 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/01/18	06 : 47	GlobeNewswire Inc.	NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/01/09	22 : 00	GlobeNewswire Inc.	NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2024/01/02	21 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2023/12/05	07 : 19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2023/12/05	06 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2023/11/13	23 : 45	GlobeNewswire Inc.	NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2023/11/09	08 : 13	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2023/11/09	08 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2023/11/09	08 : 09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2023/11/09	08 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2023/11/08	06 : 05	GlobeNewswire Inc.	NGM Bio to Participate in Upcoming Investor Conferences	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2023/11/03	05 : 12	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2023/11/03	05 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:NGM	NGM Biopharmaceuticals Inc
2023/11/03	05 : 01	GlobeNewswire Inc.	NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights	NASDAQ:NGM	NGM Biopharmaceuticals Inc

Showing the most relevant articles for your search:NASDAQ:NGM

1 2 3 4 5 6 7 8 9 10 次へ >>

Matsui Secs Uspn Adr (PK)

Outside the Box Coin

Lux Health Tech Acquisit...

XTMGS7ACE CHF INAV

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約